Last reviewed · How we verify
Remsima
At a glance
| Generic name | Remsima |
|---|---|
| Sponsor | Ghurki Trust and Teaching Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (PHASE1, PHASE2)
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- MIS-C Comparative Effectiveness Study (PHASE2, PHASE3)
- Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
- A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
- Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? (NA)
- Post-Operative Crohn's Disease Outcome in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |